SCHEMBL17679285

SCHEMBL17679285

Cc1ccc(C(=O)C(C)(C)C)c(C2CC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.40
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
KDM4C Q9H3R0 1/20 0.36
HSD17B2 P37059 3/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
HSD17B1 P14061 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
ADORA2A P29274 1/20 0.34
CCR1 P32246 1/20 0.34
CCR2 P41597 1/20 0.34
HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27436953 0.82 PTGDR2 (0.44) PTGDR2DRD2DRD4DRD3KDM4C
SCHEMBL17679283 0.82 PDK1 (0.43) PTGDR2HCRTR1HCRTR2HSD11B1RIPK1
SCHEMBL16421197 0.81 CSNK2A1 (0.48) PTGDR2DRD2DRD4DRD3KDM4C
SCHEMBL30410929 0.81 CSNK2A1 (0.48) PTGDR2DRD2DRD4DRD3KDM4C
SCHEMBL17682016 0.81 DRD2 (0.44) PTGDR2DRD2DRD4DRD3KDM4C
SCHEMBL17679284 0.80 PTGDR2 (0.45) PTGDR2NPC1RAB9AHCRTR1HCRTR2
SCHEMBL2946563 0.79 PTGDR2 (0.42) PTGDR2DRD2DRD4DRD3KDM4C
Hydrochloric Acid SCHEMBL5614018 0.78 PTGDR2 (0.41) PTGDR2DRD2DRD4DRD3KDM4C
SCHEMBL17448843 0.77 HSD11B1 (0.44) HCRTR1HCRTR2ADORA2AHSD11B1LMNA
SCHEMBL16951724 0.77 PDK2 (0.46) PTGDR2KDM4CTAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160102073-A1 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102073-A1 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CRHR2 PTGDR2 250/4885DRD2 168/4885DRD4 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.